The observed interaction between ApoM, NT-pro-BNP, and dapagliflozin therapy is consistent with unique biology related to SGLT2i since, if ApoM were merely a marker of inflammation in HF patients, we would expect to observe a similar inverse relationship with NT-pro-BNP in patients randomized to placebo. The gene discussed is NPPB; the disease is hydrops fetalis.